English

TAIPEI, Taiwan and SAN DIEGO, Calif., September 21, 2022 — Polaris Group (TWSE: 6550), a multinational biopharmaceutical company focused on research and development of novel biological drugs for cancer and other metabolic diseases, today announced top-line efficacy and safety data from the Phase 2/3 ATOMIC Study, a global, multi-center, randomized, double-blind, placebo-controlled trial of ADI-PEG 20 in combination with Pemetrexed and Cisplatin in patients with unresectable Malignant Pleural Mesothelioma (MPM) with biphasic or sarcomatoid histology.

TAIPEI, Taiwan and SAN DIEGO, Calif., June 6, 2022 – Polaris Group (“Polaris”) (TWSE: 6550), a multinational biopharmaceutical company focused on research and development of novel biological drugs for cancer and other metabolic diseases

The Taiwan Stock Exchange convened its 755th “Listing Review Committee for Securities” on March 4, 2022, to deliberate on the initial application for primary listing of shares by foreign issuer Polaris Group (Cayman Islands). The deliberation result: Approved.

Polaris, a multinational biotechnology company, has signed a corporate research sponsorship agreement with the Vaccine Research Center at the University of California, Irvine (UCI) to jointly fund the development of “Fluvid,” a universal messenger RNA (mRNA) vaccine targeting influenza and coronaviruses.

Polaris Group (TWSE:6550) rush to the stock exchange to apply for the first listing of shares before the end of 2021! Polaris Group submitted an application for listing on the 27th. It is the second foreign company to apply for the first listing in this (2021) year.

Polaris Group has entered into an agreement with the University of California,Irvine(UCI) to develop a universal influenza and coronavirus vaccine.

Polaris Group (TWSE:6550) announced today that Dr. Philip Felgner of the University of California, Irvine will officially join the Polaris Technical Advisory Board on September 1.

Polaris Pharmaceuticals announced today that Dr. Yali Tsai has joined Polaris as Vice President of Gene Delivery Technology. With over 25 years of hands-on experience in drug delivery technology and manufacturing, Dr. Tsai has developed a wide range of drugs, including injectable drugs, ophthalmic drugs and skin drugs, and has extensive experience in the development of specialty dosage forms such as microlipids, nanoemulsions and suspension particles.

Polaris Group (TWSE:6550) held its 2021 Annual General Meeting on August 23, announcing the launch of the world’s first Phase III clinical trial for a single-agent liver cancer treatment using genetic biomarker screening. The Polaris R&D team analyzed the genes of patients who had previously participated in liver cancer clinical trials and discovered that liver cancer patients with specific genetic markers demonstrated significant therapeutic efficacy when treated with ADI.

After consultation with FDA, Polaris will follow Data and Safety Monitoring Board’s (DSMB) recommendation to stop Phase III study in lung mesothelioma due to current success and difficulty in continued enrollment